United Statesbtc

STAAR Surgical (NASDAQ:STAA) reported first-quarter net sales of $93.5 million, an 119.6% increase over the $42.6 million recorded in the first quarter of 2025.

BeOne Medicines (NASDAQ:ONC) announced that Beqalzi is now authorized for MCL patients who have previously been treated with a Bruton’s tyrosine kinase (BTK) inhibitor.

Veru (NASDAQ:VERU) reported a net loss of $2.7 million, or $0.12 per share, for the three months ended March 31, 2026.

Compass Pathways (NASDAQ:CMPS) reported first-quarter net income of $91.2 million, or $0.71 per basic share, a dramatic reversal from the $17.9 million loss recorded in the same period last year.

Immunic (NASDAQ:IMUX) announced Wednesday that it ended the first quarter with $186.6 million in cash and cash equivalents, a significant increase from year-end 2025.

Pfizer (NYSE:PFE) announced Wednesday that European regulators have cleared Hympavzi for adolescents and adults with hemophilia A or B with inhibitors, marking a significant expansion for the non-factor therapy in the 27 EU member states, Iceland, Liechtenstein, and Norway.

Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.

Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company developing treatments for metabolic and liver diseases, reported its first-quarter 2026 financial results and provided a business update.

Voyager Therapeutics (NASDAQ:VYGR) achieved a critical regulatory milestone this week, presenting positive three-month toxicology data for its lead Alzheimer’s disease candidate, VY1706.

Zenas BioPharma (NASDAQ:ZBIO) announced that it is on track to transition into a commercial-stage company, with plans to submit its first Biologics License Application (BLA) to the U.S. Food and Drug Administration this quarter.